BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND SSX1, MGC5162, 6756, ENSG00000126752, RP11-552E4_1, SSRC, MGC150425, Q16384 AND Clinical Outcome
447 results:

  • 1. Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
    Fontanges Q; Dubos P; Lesluyes T; Laizet Y; Velasco V; Meléndez B; D'Haene N; Oliva E; Young RH; Mayeur L; Rebier F; Alamé M; Larmonier C; Devouassoux-Shisheboran M; Arnould L; Soubeyran I; Chakiba C; Floquet A; Babin G; Guyon F; Mery E; Le Guellec S; Noël JC; Croce S; Chibon F
    Genes Chromosomes Cancer; 2024 Mar; 63(3):e23229. PubMed ID: 38481055
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Impact of histological subtypes on clinical outcome of endocervical adenocarcinoma.
    Tian X; Liu P; Kang S; Cui Z; Sun L; Lang J; Chen C
    Eur J Surg Oncol; 2024 Apr; 50(4):107977. PubMed ID: 38373385
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
    Recio F; Scalise CB; Loar P; Lumish M; Berman T; Peddada A; Kalashnikova E; Rivero-Hinojosa S; Beisch T; Nicosia B; Farmer T; Dutta P; Malhotra M; ElNaggar AC; Liu MC; Vaccarello L; Holloway RW
    Gynecol Oncol; 2024 Mar; 182():63-69. PubMed ID: 38262240
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK.
    Evans I; Reisel D; Jones A; Bajrami A; Nijjar S; Solangon SA; Arora R; Redl E; Schreiberhuber L; Ishaq-Parveen I; Rothärmel J; Herzog C; Jurkovic D; Widschwendter M
    Lancet Oncol; 2023 Dec; 24(12):1375-1386. PubMed ID: 37944542
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The mRNA and protein levels of the glycolytic enzymes lactate dehydrogenase A (LDHA) and phosphofructokinase platelet (PFKP) are good predictors of survival time, recurrence, and risk of death in cervical cancer patients.
    Bolaños-Suárez V; Alfaro A; Espinosa AM; Medina-Martínez I; Juárez E; Villegas-Sepúlveda N; Gudiño-Zayas M; Gutiérrez-Castro A; Román-Bassaure E; Salinas-Nieves ME; Bruno-Muñoz S; Aranda C; Flores-Herrera O; Berumen J
    Cancer Med; 2023 Jul; 12(14):15632-15649. PubMed ID: 37326348
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Circulating adrenal 11-oxygenated androgens are associated with clinical outcome in endometrial cancer.
    Dahmani C; Caron P; Simonyan D; Turcotte V; Grégoire J; Plante M; Guillemette C
    Front Endocrinol (Lausanne); 2023; 14():1156680. PubMed ID: 37288302
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
    Reijnen C; Vrede SW; Eijkelenboom A; Draak R; Sweegers S; Snijders MPLM; van Gestel P; Pijnenborg JMA; Bulten J; Küsters-Vandevelde HVN
    Cancer Med; 2023 Jun; 12(11):12365-12376. PubMed ID: 37081760
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
    Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
    Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
    Madariaga A; Garg S; Tchrakian N; Dhani NC; Jimenez W; Welch S; MacKay H; Ethier JL; Gilbert L; Li X; Rodriguez A; Chan L; Bowering V; Clarke B; Zhang T; King I; Downs G; Stockley T; Wang L; Udagani S; Oza AM; Lheureux S
    Nat Commun; 2023 Mar; 14(1):1452. PubMed ID: 36922497
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The MRI-guided two adaptive brachytherapy fractions versus one adaptive brachytherapy fraction in one application for the cervical cancer: a retrospective study.
    Song S; Han D; Zhang N; Mao Z; Guo X; Cheng G
    Radiat Oncol; 2023 Mar; 18(1):46. PubMed ID: 36879287
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. clinical outcome analysis of intramural myoma greater than 8 cm in diameter removed during caesarean section: a retrospective study.
    Shi C; Chen J; Chen A
    BMC Womens Health; 2023 Feb; 23(1):60. PubMed ID: 36774454
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T-cell infiltration.
    Wang X; Fang A; Peng Y; Yu J; Yu C; Xie J; Zheng Y; Song L; Li P; Li J; Kang X; Lin Y; Li W
    J Cell Mol Med; 2023 Mar; 27(5):609-621. PubMed ID: 36756714
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Early outcomes of abbreviated multi-fractionated brachytherapy schedule for cervix cancer during COVID-19 pandemic.
    Chopra S; Mulani J; Mittal P; Singh M; Shinde A; Gurram L; Scaria L; Aravindakshan D; Kohle S; Rane P; Ghadi Y; Rath S; Ghosh J; Gulia S; Gupta S; Kinhikar R; Laskar S; Agarwal JP
    Brachytherapy; 2023; 22(2):125-131. PubMed ID: 36585283
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. uterine Myoma Position-based Radiofrequency Ablation (UMP-b RFA): 36 months follow-up clinical outcomes.
    Fasciani A; Turtulici G; Pedullà A; Sirito R
    Eur J Obstet Gynecol Reprod Biol; 2023 Feb; 281():23-28. PubMed ID: 36527825
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Is microcystic, elongated, and fragmented pattern of myometrial invasion in endometrioid endometrial carcinoma associated with survival?
    Altındağ SD; Yiğit S; Şen S
    Turk J Med Sci; 2022 Oct; 52(5):1569-1579. PubMed ID: 36422476
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: clinical outcome and prognostic factors.
    Ka K; Laville A; Rassy E; Ayachi RE; Pautier P; Ba MB; Bockel S; Achkar S; Espenel S; Maulard A; Morice P; Gouy S; Haie-Meder C; Sun R; Chargari C
    Gynecol Oncol; 2023 Jan; 168():32-38. PubMed ID: 36370612
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The Relevance of High Temperatures and Short Time Intervals Between Radiation Therapy and Hyperthermia: Insights in Terms of Predicted Equivalent Enhanced Radiation Dose.
    Kok HP; Herrera TD; Crezee J
    Int J Radiat Oncol Biol Phys; 2023 Mar; 115(4):994-1003. PubMed ID: 36288756
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
    López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
    J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Epidemiology and Molecular Biology of HPV Variants in Cervical cancer: The State of the Art in Mexico.
    Muñoz-Bello JO; Carrillo-García A; Lizano M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955700
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 23.